Find Funding Opportunities

Returning 155 results

NeuroNEXT Infrastructure Resource Access (X01)

PAR
Thursday, April 30, 2015
Tuesday, March 13, 2018
X01
PAR-15-195

Funding Opportunity Purpose

This FOA encourages applications for exploratory clinical trials of investigational agents (drugs, biologics, surgical therapies or devices) that may contribute to the justification for and provide the data required for designing a future trial, for biomarker validation studies, or for proof of mechanism clinical studies. Diseases chosen for study should be based on the NINDS' strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm). Successful applicants will be given access to the NeuroNEXT infrastructure. Following peer review, NINDS will prioritize and order trials that are given access to the NeuroNEXT infrastructure. The NeuroNEXT Clinical Coordinating Center (CCC) will work with the successful applicant to efficiently implement the proposed study. The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support. The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol.

Developing the Therapeutic Potential of the Endocannabinoid System for Pain Treatment (R01)

PA
Tuesday, April 28, 2015
Saturday, September 8, 2018
R01
PA-15-188

Funding Opportunity Purpose

The purpose of this Funding Opportunity Announcement (FOA) is to support projects that will elucidate the therapeutic potential of the cannabinoids and endocannabinoid system in the development of mechanism-based therapies for pain.

Summer Research Education Experience Programs (R25)

PAR
Thursday, April 16, 2015
Thursday, May 24, 2018
R25
PAR-15-184

Funding Opportunity Purpose

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this R25 program is to support educational activities that foster a better understanding of biomedical, behavioral and clinical research and its implications. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Research Experiences for high school, undergraduate and science teachers during the summer academic break.

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Therapeutic Agent Identification and Characterization to Support Therapeutic Discovery (R21/R33)

PAR
Friday, December 12, 2014
Tuesday, May 8, 2018
R21/R33
PAR-15-070

Funding Opportunity Purpose

This funding opportunity announcement (FOA) encourages research grant applications to develop in vitro and/or ex vivo assays and conduct iterative screening efforts to identify and characterize potential therapeutic agents for neurological disorders. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for NINDS Cooperative Research to Enable and Advance Translational Enterprises program (CREATE) for biologics, biotechnology products, the Blueprint Neurotherapeutics Network (BPN) for small molecules, or other translational program.

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Pharmacodynamics and In vivo Efficacy Studies for Small Molecules and Biologics/Biotechnology Products (R21/R33)

PAR
Friday, December 12, 2014
Translational Research
Tuesday, May 8, 2018
R21/R33
PAR-15-071

Funding Opportunity Purpose

This FOA provides funding to conduct pharmacodynamics, pharmacokinetics, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological disorders. Therapeutic agents may include but are not limited to small molecules, biologics or biotechnology-derived products. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for NINDS Cooperative Research to Enable and Advance Translational Enterprises program (CREATE) for biologics, biotechnology products, the Blueprint Neurotherapeutics Network (BPN) for small molecules, or other translational program.

Pages